Drugs / Self-injectable epinephrine
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02478398 Background | Jul 2015 → Nov 2018 | seasonal allergic rhinitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Self-injectable epinephrine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02478398 ↗ |
| Route | Intramuscular | “Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as...” NCT02478398 ↗ |